Response to Comments: MolDX: Genetic Testing for Heritable Thoracic Aortic Disease (DL39989)

This document (A60220) is a response-to-comments notice for MolDX LCD DL39989 (Genetic Testing for Heritable Thoracic Aortic Disease), recording that the comment period ran 2024-08-29 to 2024-10-12 and that the notice period begins 2025-07-03 with effective date 2025-08-17. It documents that provider comments were received and directs readers to LCD DL39989 for the actual coverage criteria; the response notice itself does not establish clinical coverage rules.

"Comment period for MolDX LCD DL39989 began 2024-08-29 and ended 2024-10-12."

Sign up to see full coverage criteria, indications, and limitations.